Daxor Corporation (DXR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Daxor Corporation (DXR) has a cash flow conversion efficiency ratio of 0.013x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($467.04K) by net assets ($35.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Daxor Corporation for the company's overall valuation and market capitalisation.
Daxor Corporation - Cash Flow Conversion Efficiency Trend (1985–2024)
This chart illustrates how Daxor Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Daxor Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Daxor Corporation ranked by their cash flow conversion efficiency. Explore Daxor Corporation (DXR) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pasupati Acrylon Limited
NSE:PASUPTAC
|
0.013x |
|
Regis Corporation Common Stock
NASDAQ:RGS
|
0.022x |
|
Shanghai Jin Jiang International Industrial Investment Co Ltd B
SHG:900914
|
0.042x |
|
Dynamic Medical Technologies
TWO:4138
|
-0.016x |
|
Mordechai Aviv Taasiot Beniyah 1973 Ltd
TA:AVIV
|
-0.019x |
|
Titijaya Land Bhd
KLSE:5239
|
-0.011x |
|
PicoCELA Inc. American Depositary Shares
NASDAQ:PCLA
|
-0.664x |
|
Enex Co.Ltd
KO:011090
|
-0.124x |
Annual Cash Flow Conversion Efficiency for Daxor Corporation (1985–2024)
The table below shows the annual cash flow conversion efficiency of Daxor Corporation from 1985 to 2024. View latest Daxor Corporation stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $35.79 Million | $25.69K | 0.001x | +100.67% |
| 2023-12-31 | $34.01 Million | $-3.66 Million | -0.107x | -304.70% |
| 2022-12-31 | $28.97 Million | $-769.30K | -0.027x | +79.64% |
| 2021-12-31 | $21.15 Million | $-2.76 Million | -0.130x | +16.47% |
| 2020-12-31 | $15.68 Million | $-2.45 Million | -0.156x | -164.05% |
| 2019-12-31 | $12.77 Million | $3.11 Million | 0.244x | +342.04% |
| 2018-12-31 | $13.06 Million | $-1.32 Million | -0.101x | -18.18% |
| 2017-12-31 | $13.76 Million | $-1.17 Million | -0.085x | -182.11% |
| 2016-12-31 | $15.34 Million | $1.59 Million | 0.104x | -91.92% |
| 2015-12-31 | $14.43 Million | $18.53 Million | 1.284x | +10776.23% |
| 2014-12-31 | $24.58 Million | $-295.64K | -0.012x | +96.49% |
| 2013-12-31 | $26.37 Million | $-9.04 Million | -0.343x | -368.80% |
| 2012-12-31 | $35.11 Million | $4.48 Million | 0.128x | +170.98% |
| 2011-12-31 | $36.22 Million | $-6.51 Million | -0.180x | -48.43% |
| 2010-12-31 | $47.00 Million | $-5.69 Million | -0.121x | -9.77% |
| 2009-12-31 | $47.63 Million | $-5.25 Million | -0.110x | -18.67% |
| 2008-12-31 | $43.46 Million | $-4.04 Million | -0.093x | -62.40% |
| 2007-12-31 | $54.92 Million | $-3.14 Million | -0.057x | +24.08% |
| 2006-12-31 | $45.64 Million | $-3.44 Million | -0.075x | -152.57% |
| 2005-12-31 | $38.74 Million | $-1.16 Million | -0.030x | +34.97% |
| 2004-12-31 | $39.88 Million | $-1.83 Million | -0.046x | -51.31% |
| 2003-12-31 | $36.42 Million | $-1.10 Million | -0.030x | -378.23% |
| 2002-12-31 | $33.55 Million | $-212.77K | -0.006x | -201.10% |
| 2001-12-31 | $35.33 Million | $221.63K | 0.006x | +327.81% |
| 2000-12-31 | $38.67 Million | $-106.49K | -0.003x | +82.89% |
| 1999-12-31 | $29.28 Million | $-471.20K | -0.016x | +28.99% |
| 1998-12-31 | $35.30 Million | $-800.00K | -0.023x | -286.40% |
| 1997-12-31 | $32.90 Million | $400.00K | 0.012x | +93.31% |
| 1996-12-31 | $31.80 Million | $200.00K | 0.006x | -32.70% |
| 1995-12-31 | $32.10 Million | $300.00K | 0.009x | -70.93% |
| 1994-12-31 | $31.10 Million | $1.00 Million | 0.032x | -39.65% |
| 1993-12-31 | $24.40 Million | $1.30 Million | 0.053x | -48.34% |
| 1992-12-31 | $22.30 Million | $2.30 Million | 0.103x | +64.16% |
| 1991-12-31 | $19.10 Million | $1.20 Million | 0.063x | -42.64% |
| 1990-12-31 | $21.00 Million | $2.30 Million | 0.110x | +509.62% |
| 1989-12-31 | $18.70 Million | $-500.00K | -0.027x | -114.94% |
| 1988-12-31 | $19.00 Million | $3.40 Million | 0.179x | +59.93% |
| 1986-12-31 | $14.30 Million | $1.60 Million | 0.112x | -19.81% |
| 1985-12-31 | $12.90 Million | $1.80 Million | 0.140x | -- |
About Daxor Corporation
Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corpo… Read more